ASX-173 is an orally active asparagine synthetase (ASNS) inhibitor with an IC50 of 0.113 µM and a Ki of 0.4 nM. It enhances the anticancer activity of L-Asparaginase (ASNase). When combined with ASNase, ASX-173 disrupts nucleotide synthesis and induces cell cycle arrest, apoptosis (apoptosis), and autophagy (autophagy) in leukemia cells. This combination also slows the growth of OCI-AML2 xenograft tumors. ASX-173 is applicable in research on acute lymphoblastic leukemia, acute myeloid leukemia, colorectal cancer, and other cancers.
